ATE553098T1 - Verfahren zur herstellung von rosuvastatin- calcium - Google Patents

Verfahren zur herstellung von rosuvastatin- calcium

Info

Publication number
ATE553098T1
ATE553098T1 AT08702369T AT08702369T ATE553098T1 AT E553098 T1 ATE553098 T1 AT E553098T1 AT 08702369 T AT08702369 T AT 08702369T AT 08702369 T AT08702369 T AT 08702369T AT E553098 T1 ATE553098 T1 AT E553098T1
Authority
AT
Austria
Prior art keywords
rosuvastatin calcium
producing rosuvastatin
producing
calcium
dihydroxyhept
Prior art date
Application number
AT08702369T
Other languages
English (en)
Inventor
Ramesh Dandala
Sambhu Prasad Sarma Mallela
Sukumar Nandi
Gangadhar Bhima Shankar Nangi
Sunil Kumar Buridipadu
Sivakumaran Meenakshisunderam
Original Assignee
Aurobindo Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aurobindo Pharma Ltd filed Critical Aurobindo Pharma Ltd
Application granted granted Critical
Publication of ATE553098T1 publication Critical patent/ATE553098T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT08702369T 2007-02-08 2008-02-04 Verfahren zur herstellung von rosuvastatin- calcium ATE553098T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN277CH2007 2007-02-08
IN1121CH2007 2007-05-29
PCT/IB2008/000290 WO2008096257A1 (en) 2007-02-08 2008-02-04 An improved process for preparation of rosuvastatin calcium

Publications (1)

Publication Number Publication Date
ATE553098T1 true ATE553098T1 (de) 2012-04-15

Family

ID=39323006

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08702369T ATE553098T1 (de) 2007-02-08 2008-02-04 Verfahren zur herstellung von rosuvastatin- calcium

Country Status (7)

Country Link
US (1) US8212035B2 (de)
EP (1) EP2125754B1 (de)
AT (1) ATE553098T1 (de)
AU (1) AU2008212622B2 (de)
CA (1) CA2677809A1 (de)
ES (1) ES2385623T3 (de)
WO (1) WO2008096257A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6835838B2 (en) * 2002-01-28 2004-12-28 Novartis Ag Process for the manufacture of organic compounds
US7851624B2 (en) 2003-12-24 2010-12-14 Teva Pharamaceutical Industries Ltd. Triol form of rosuvastatin and synthesis of rosuvastatin
JP2009531466A (ja) 2007-04-18 2009-09-03 テバ ファーマシューティカル インダストリーズ リミティド ＨＭＧ−ＣｏＡ還元酵素阻害剤の中間体の製造方法
WO2010071595A1 (en) * 2008-12-19 2010-06-24 Sekab Biofuels & Chemicals Ab Denaturant-containing, ethanol-based liquid
JP6562213B2 (ja) 2013-08-30 2019-08-21 日産化学株式会社 光学活性５−ヒドロキシ−３−ケトエステル類の製造方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
GB9903472D0 (en) 1999-02-17 1999-04-07 Zeneca Ltd Chemical process
US6872715B2 (en) * 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
GB0204129D0 (en) * 2002-02-21 2002-04-10 Novartis Ag Process for the manufacture of organic compounds
EP1585736A2 (de) 2002-05-21 2005-10-19 Ranbaxy Laboratories, Ltd. Verfahren zur herstellung von rosuvastatin
GB0218781D0 (en) * 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
US7566782B2 (en) 2002-12-10 2009-07-28 Ranbaxy Laboratories Limited Process for the preparation of rosuvastatin
CA2537271A1 (en) * 2003-08-28 2005-03-17 Teva Pharmaceutical Industries, Ltd. Process for preparation of rosuvastatin calcium
EP1678148A1 (de) * 2003-10-22 2006-07-12 Ranbaxy Laboratories Limited Verfahren zur herstellung von amorphen rosuvastatin-calcium
GB0324791D0 (en) * 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
TW200526596A (en) * 2003-11-24 2005-08-16 Teva Pharma Crystalline ammonium salts of rosuvastatin
US20080234302A1 (en) * 2004-09-27 2008-09-25 Mohammad Rafeeq Novel Processes for Preparing Amorphous Rosuvastatin Calcium and a Novel Polymorphic Form of Rosuvastatin Sodium
US20070167625A1 (en) * 2005-02-22 2007-07-19 Anna Balanov Preparation of rosuvastatin
US20070037979A1 (en) * 2005-02-22 2007-02-15 Valerie Niddam-Hildesheim Preparation of rosuvastatin
TWI353981B (en) * 2005-02-22 2011-12-11 Teva Pharma Preparation of rosuvastatin
WO2006100689A1 (en) 2005-03-22 2006-09-28 Unichem Laboratories Limited Process for preparation of rosuvastatin
US20080161560A1 (en) * 2005-04-04 2008-07-03 Pandurang Balwant Deshpande Process for Preparation of Calcium Salt of Rosuvastatin
WO2006136407A1 (en) 2005-06-24 2006-12-28 Lek Pharmaceuticals D.D. Process for preparing amorphous rosuvastatin calcium free of impurities
WO2006136408A2 (en) * 2005-06-24 2006-12-28 Lek Pharmaceuticals D.D. Process for preparing pure amorphous rosuvastatin calcium
CZ299215B6 (cs) 2005-06-29 2008-05-21 Zentiva, A. S. Zpusob výroby hemivápenaté soli (E)-7-[4-(4-fluorofenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3R,5S)-3,5-dihydroxy-6-heptenovékyseliny
GB0514078D0 (en) 2005-07-08 2005-08-17 Astrazeneca Uk Ltd Chemical process
WO2007017117A1 (en) * 2005-07-28 2007-02-15 Lek Pharmaceuticals D.D. Process for the synthesis of rosuvastatin calcium
EP1919880A2 (de) * 2005-08-16 2008-05-14 Teva Pharmaceutical Industries Ltd. Rosuvastatincalcium mit geringem gehalt an salzhaltigen nebenprodukten
KR101019450B1 (ko) * 2005-10-03 2011-03-07 테바 파마슈티컬 인더스트리즈 리미티드 로수바스타틴의 부분입체 이성질체 정제
WO2007099561A1 (en) 2006-02-27 2007-09-07 Cadila Healthcare Limited Process for preparing rosuvastatin calcium
US8404841B2 (en) 2006-10-09 2013-03-26 Msn Laboratories Limited Process for the preparation of statins and their pharmaceutically acceptable salts thereof
EP2022784A1 (de) 2007-08-08 2009-02-11 LEK Pharmaceuticals D.D. Verfahren zur Herstellung des Methylesters von Rosuvastatin
HU230637B1 (hu) 2007-10-12 2017-05-29 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Eljárás rosuvastatin intermedierek előállítására

Also Published As

Publication number Publication date
US8212035B2 (en) 2012-07-03
WO2008096257A1 (en) 2008-08-14
CA2677809A1 (en) 2008-08-14
ES2385623T3 (es) 2012-07-27
EP2125754A1 (de) 2009-12-02
EP2125754B1 (de) 2012-04-11
US20090312547A1 (en) 2009-12-17
AU2008212622B2 (en) 2011-01-27
AU2008212622A1 (en) 2008-08-14

Similar Documents

Publication Publication Date Title
TWI341310B (en) Improved production of (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid calcium salt
MY142615A (en) Crystalline form of bis [ (e)-7-4(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r, 5s)-3,5-dihydroxyhept-6 -enoic acid] calcium salt
IS8478A (is) Aðferð til að framleiða kalsíumsalt rósúvatatín (E)-7-[4-(4-flúorfenýl)-6-ísóprópýl-2-[metýl(metýlsúlfónýl)amínó]pýrimídín-5-ýl] (3R,5S)-3,5-díhýdroxýhept-6-enósýru og kristölluð milliefni þess
WO2009157014A3 (en) A process for preparing hmg-coa reductase inhibitors and intermediates
EE05288B1 (et) 7-[4-(4-fluorofenl)-6-isopropl-2-metl(metlsulfonl)amino]primidiin-5-l] -(3R,5S)-3,5- dihdrokshept-6-enohappe kristalsed soolad
DK1144389T3 (da) Krystallinsk bis(E)-7-[4-(4-fluorphenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-ensyre]calciumsalt
EA201070410A1 (ru) Твердые формы (s)-этил-2-амино-3-(4-(2-амино-6-((r)-1-(4-хлор-2-(3-метил-1h-пиразол-1-ил)фенил)-2,2,2-трифторэтокси)пиримидин-4-ил)фенил)пропаноата и способы их применения
ATE553098T1 (de) Verfahren zur herstellung von rosuvastatin- calcium
EA201390771A1 (ru) Способ получения фармацевтических промежуточных соединений высокой чистоты
DE602004004679D1 (de) Verfahren zur herstellung des hemicalciumsalzes von (e)-7-ä4-(4-fluorphenyl)-6-isopropyl-2-ämethyl(methylsulfonyl)aminoüpyrimidin-5-ylü(3r,5s)-3,5-dihydroxy-6-heptensäure
NZ611072A (en) Method for preparing rosuvastatin salts
WO2009128091A3 (en) Crystalline form of(7-[4-(4-fluorophenyl)-6-isopropyl-2-(n- methyl-n-methylsulfonylamino)pyrimidin-5-yl]-(3r,5s)- dihydroxy-(e)-6-heptenoic acid intermediate, process for preparing the same and use thereof
WO2012011129A3 (en) Novel polymorph of bis[(e)-7-[4-(4-fluorophenyl)-6-iso-propyl-2-[methyl (methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid] calcium salt
TR200800269A2 (tr) Stabil farmasötik formülasyon ve hazırlama yöntemleri
AR043594A1 (es) Un procedimiento para la preparacion de la sal de calcio del acido (e)-7-[4-(4-fluorofenil)-6-isopropil-2-[metil(metil-sulfonil)amino]pirimidin-5-il] (3r,5s)-3,5-dihidroxihept-6-enoico y compuesto utilizable en dicho procedimiento
EA201200765A1 (ru) Способ получения полиморфной модификации холиновой соли производного пиримидин-5-илуксусной кислоты
EA201000214A1 (ru) Способ получения производных пентадикарбоновой кислоты